Mackenzie Edmondson

Development and evaluation of a novel digital pathology image analysis pipeline for prediction of clinical outcomes with the TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) in triple-negative breast cancer (TNBC).

Sara M. Tolaney, John Kang, Jeong Hwan Kook, Zhongliang Zhou et autres

1026 Background: Digital pathology (DP), including artificial intelligence (AI)-based image analysis methods, enables IHC biomarker assessment on a continuous scale, potentially improving precision and accuracy versus conventional IHC scoring. DP may also capture features relevant to ADC response that traditional methods miss. …

us (code pays fourni par la source)

Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial

Thomas; https://orcid.org/0000-0001-7760-4724 Powles, Yen‐Hwa Chang, Yoshiaki Yamamoto, Jose Munoz et autres

Circulating tumor DNA (ctDNA) is emerging as a potential biomarker in early-stage urothelial cancer, but its utility in metastatic disease remains unknown. In the phase 3 KEYNOTE-361 study, pembrolizumab with and without chemotherapy was compared with chemotherapy alone in patients with metastatic …